scholarly journals Clinical Stage, Prostate-Specific Antigen and Gleason Grade to Predict Extracapsular Disease or Nodal Metastasis in Men with Newly Diagnosed, Previously Untreated Prostate Cancer

1997 ◽  
Vol 5 (Suppl. 1) ◽  
pp. 90-90
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Clinical Stage ◽  
Specific Antigen ◽  
Nodal Metastasis ◽  
Gleason Grade ◽  
Newly Diagnosed

Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer

1999 ◽  
Vol 17 (5) ◽  
pp. 1499-1499 ◽  
Author(s):  
Michael W. Kattan ◽  
Thomas M. Wheeler ◽  
Peter T. Scardino
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Prostate Specific Antigen ◽  
Clinical Stage ◽  
Specific Antigen ◽  
Disease Recurrence ◽  
Gleason Grade ◽  
Antigen Level ◽  
Serum Prostate Specific Antigen

PURPOSE: Although models exist that place patients into discrete groups at various risks for disease recurrence after surgery for prostate cancer, we know of no published work that combines pathologic factors to predict an individual's probability of disease recurrence. Because clinical stage and biopsy Gleason grade only approximate pathologic stage and Gleason grade in the prostatectomy specimen, prediction of prognosis should be more accurate when postoperative information is added to preoperative variables. Therefore, we developed a postoperative nomogram that allows more accurate prediction of probability for disease recurrence for patients who have received radical prostatectomy as treatment for prostate cancer, compared with the preoperative nomogram we previously published. PATIENTS AND METHODS: By Cox proportional hazards regression analysis, we modeled the clinical and pathologic data and disease follow-up for 996 men with clinical stage T1a-T3c NXM0 prostate cancer who were treated with radical prostatectomy by a single surgeon at our institution. Prognostic variables included pretreatment serum prostate-specific antigen level, specimen Gleason sum, prostatic capsular invasion, surgical margin status, seminal vesicle invasion, and lymph node status. Treatment failure was recorded when there was either clinical evidence of disease recurrence, a rising serum prostate-specific antigen level (two measurements of 0.4 ng/mL or greater and rising), or initiation of adjuvant therapy. Validation was performed on this set of men and a separate sample of 322 men from five other surgeons' practices from our institution. RESULTS: Cancer recurrence was noted in 189 of the 996 men, and the recurrence-free group had a median follow-up period of 37 months (range, 1 to 168 months). The 7-year recurrence-free probability for the cohort was 73% (95% confidence interval, 68% to 76%). The predictions from the nomogram appeared to be accurate and discriminating, with a validation sample area under the receiver operating characteristic curve (ie, a comparison of the predicted probability with the actual outcome) of 0.89. CONCLUSION: A postoperative nomogram has been developed that can be used to predict the 7-year probability of disease recurrence among men treated with radical prostatectomy.

scholarly journals Correlation of serum prostate specific antigen with clinical, radiological and pathological variables in patients with prostate enlargement

2019 ◽  
Vol 6 (12) ◽  
pp. 4408
Author(s):  
Tinku Antony ◽  
Raghav Talwar ◽  
Tina Thomas ◽  
Vikram Trehan ◽  
Shrikant Manwantkar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Clinical Stage ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Threshold Level ◽  
Gleason Grade ◽  
Chi Square ◽  
Abdominal Ultrasonography ◽  
Prostate Enlargement

Background: Prostate enlargement encompasses a spectrum of disorders ranging from benign to malignant. For diagnostic prostatic biopsies no clear prostate specific antigen (PSA) threshold level exists. The study correlates PSA with various clinical data (age of patient, international prostate severity score (IPSS), digital rectal examination (DRE) finding), radiological data (prostate volume) and pathological data (Gleason grade, prostate cancer stage) to aid decision making on treatment of prostate enlargement.Methods: 101 men aged more than 50 years with fresh LUTS and grade 1 or more prostate enlargement on DRE were enrolled. They were worked up with transabdominal ultrasonography, serum PSA and prostate biopsy (when indicated). A descriptive statistical analysis was done for correlation by applying Pearson’s Chi square test for significance.Results: Mean serum PSA value was found to increase with age and higher IPSS score. Mean serum PSA levels were found to rise with grade of prostatomegaly. No significant correlation was seen between serum PSA values and Gleason grade or clinical stage of prostate cancer.Conclusions: Serum PSA levels has a significant correlation with age. With increasing age there is increase in serum PSA levels. Serum PSA levels has a significant correlation with International prostate symptom severity scoring. Serum PSA levels has a significant correlation with prostate size measured by trans-abdominal ultrasonography. Serum PSA levels does not show significant correlation with Gleason score or clinical stage of prostate cancer.

scholarly journals Neuroendocrine differentiation in prostate cancer

2004 ◽  
Vol 61 (5) ◽  
pp. 513-518 ◽  
Author(s):  
Snezana Cerovic ◽  
Goran Brajuskovic ◽  
Vinka Maletic-Vukotic ◽  
Sava Micic
Keyword(s):  
Prostate Cancer ◽  
Clinical Stage ◽  
Prognostic Significance ◽  
Specific Antigen ◽  
Neuron Specific Enolase ◽  
Neuroendocrine Differentiation ◽  
Current Evidence ◽  
Gleason Grade ◽  
Preoperative Serum ◽  
Significant Expression

Background. In numerous recent studies attention has been focused to neuroendocrine differentiation (NED) in prostate cancer (PC). Focal NED is present in almost all PCs, but it is prominent in only 5-10% of the carcinomas. The prognostic significance of focal NED in PC is controversial, but current evidence suggests its influence on the onset and/or conversion of hormon resistant tumor phenotype. The aim of this study was to evaluate the relationship between NED status, based only on immunohistochemical use of neuroendocrine (NE) markers, with PC grade and stage, and preoperative serum levels of prostate-specific antigen (PSA). Methods. The study included the biopsy material of 73 untreated PC patients (pts.) obtained by transurethral resection (TUR) (37 pts.), and radical retropubic prostatectomy (RRP) (36 pts.). Two representative tissue samples (tipically the block containing the largest amount of neoplasm) were selected for immunohistochemical (IMM) staining. NE cells were identified using a panel of IMM markers: chromogranin A, neuron-specific enolase, and serotonin. The level of PC exocrine differentiation was detected by monoclonal antibodies against PSA. Results. Significant expression of NE cells was demonstrated in 26 (70.2%) pts. with PC after TUR. In this group, serum preoperative PSA values ranged from 0.1 to 9.6 ng/ml. The majority of pts. with NED had low differentiated PC with Gleason grade score (GGS) >7, and normal PSA values below 4 ng/ml (77%), in clinical stage D (54%). Statistically significant correlation (p<0.01) of positive NED with higher stage and grade and low PSA values was established. Among the pts. with localized PC in whom RRP was performed (n=36), significant expression of NE cells was found in 15 pts. (41.7%), 8 (53.3%) in pT2 stage, and 7 (46.7%) in pT3 stage. Significant correlation between NED with preoperative PSA values and stage of PC in pts. with RRP was not found. Conclusion. We demonstrated the significant NED in poorly differentiated PC in patients in the advanced stage of the disease. The expression of NED in organ-confined PC did not correlate with tumor stage, but it correlated with tumor grade (GGS?7).

The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer

1995 ◽  
Vol 22 (3) ◽  
pp. 207-211 ◽  
Author(s):  
Marco Rudoni ◽  
Giuseppina Antonini ◽  
Michele Favro ◽  
Alberto Baroli ◽  
Marco Brambilla ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Bone Scintigraphy ◽  
Specific Antigen ◽  
Newly Diagnosed ◽  
Clinical Value
Sign in / Sign up

Export Citation Format

Share Document